T-cell immune balance peptide

A cellular immunity and balance technology, applied in the direction of peptides, hybrid peptides, specific peptides, etc., can solve the problems of chronic infection that have not been reported

Inactive Publication Date: 2011-05-18
夏书奇
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

SARS infects the epithelial cells of the lung, kidney and digestive tract, but no chronic infection has been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T-cell immune balance peptide
  • T-cell immune balance peptide
  • T-cell immune balance peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Preparation of T cell immune balance peptides from animal tissues

[0109] 1. Select healthy suckling pigs or non-lactating newborn cows, take fresh livers, hearts, kidneys and spleens, etc., wash them with water for injection, and shred or chop them at about 24°C;

[0110] 2. Add sterilized water for injection according to weight: volume ratio of 1:1, and homogenate repeatedly for 10 minutes at low temperature (4°C) to obtain a homogenate; put the homogenate into a low temperature of minus 60 to 70 degrees to freeze After freezing, quickly heat up the quick-thaw solution to 85°C and keep the temperature constant for 10 minutes to achieve thermal denaturation of macromolecular proteins and remove macromolecular proteins;

[0111] 3. After heat denaturation, centrifuge at 4°C, 3000 rpm for 20 minutes, discard the precipitate, and take the supernatant;

[0112] 4. Graded ultrafiltration and virus inactivation: the centrifugal supernatant is subjected to graded ultrafiltr...

Embodiment 2

[0115] Preparation of T cell immune balance peptide by chemical synthesis

[0116] The preparation of polypeptides uses the Fmoc solid-phase peptide synthesis method. First, an amino acid protected by an Fmoc group on the α-amino group is connected to an insoluble carrier through an arm, and then the α-amino group is deprotected, and the amino acid is washed with a solution- Arm - Resin. The second pre-activated α-amino protected amino acid is connected through a coupling reaction. After the condensation reaction is completed, it is washed with a solution, and the deprotection and coupling are repeated until the target peptide is obtained. Finally the peptide-arm-resin is cleaved. Peptide purification, using HPLC method, the crude peptide product is separated and purified by C18 high-pressure column, and the required effluent is tracked and collected by liquid chromatography, the sample peaks are combined, desalted, and freeze-dried to obtain a high-quality peptide.

[0117]...

Embodiment 3

[0154] ELISPOT method to detect the inhibitory effect of synthetic peptide mixture and PHGF on HBcAg-induced IFN-gamma

[0155] Using HBcAg to stimulate human peripheral blood mononuclear cells (PBMC) to induce IFN-gamma, observe the effect of different concentrations of synthetic peptide mixture and PHGF on the production of IFN-gamma, so as to reflect their regulatory effect on T cell specific immunity

[0156] experimental reagent

[0157] RPMI1640 medium and fetal bovine serum, lymphocyte separation fluid, anti-human CD3, HBcAg, synthetic decapeptide (mentioned above), PHGF, ELISPOT kit, solid heparin sodium anticoagulant, double distilled water, sterile ionized water.

[0158] experimental method

[0159] 6 healthy subjects were required to fast for at least 6 hours before blood collection. Take 5ml of peripheral blood from volunteers or patients under aseptic conditions with high-pressure sterilized blood collection tubes, anticoagulate with 100 units of heparin sodiu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a polypeptide mixture for interfering the formation of MHC (Major Histocompability Complex)-pathogenic peptide-TCR (Cell Antigen Receptor) regardless of the genetic background of patients. The formation of MHC-pathogenic peptide-TCR is interfered by the following steps of: interfering the combination of pathogenic peptide and MHC and the combination of pMHC and the specific TCR; inhibiting the formation of immunological synapse generated by a specific T-cell immunoreaction; inhibiting the number and the density of MHC-specific immunoreaction mediated pathogenic peptide-TCR in the immunological synapse; and inhibiting the transmission of an intense activation signal in the immunological synapse and negatively adjusting the ongoing intense specific immunoreaction mediated by the T-cell; weakening the activation, multiplication and effect capabilities of specific immunocyte so that extreme T-cell specific immunoreaction becomes milder and durable. The invention is used for treating diseases accompanied by the extreme T-cell specific immunoreaction, such as serious flu, SARS (Severe Acute Respiratory Syndrome), hand-foot-and-mouth diseases, viral pneumonia, bacterial infection, serious self immune diseases, and the like.

Description

technical field [0001] The present invention relates to a kind of polypeptide mixture that negatively regulates the specific immune response mediated by T cells caused by macromolecular proteins, viruses, bacteria, etc., especially excessively severe T cell specific immune responses, which can make T cells specific The sexual immune response is more mild and persistent. Background technique [0002] Drugs used for the treatment of hypersensitivity diseases such as hypersensitivity, autoimmune diseases, transplant rejection, inflammation, etc. include: ① non-specific immunosuppressants: such as chemical agents (alkylating agents and antimetabolites), hormones, fungal metabolic Products (cyclosporine A and FK-506) and some traditional Chinese medicine ingredients. Most of these preparations have obvious toxic and side effects, which can lead to a decline in the immune function of the body, increase the chance of infection, and may induce tumors after long-term use. They are m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/02A61P31/16A61P31/14A61P31/12A61P11/00A61P31/04A61P37/02
CPCC07K14/001A61K38/00A61P11/00A61P31/00A61P31/04A61P31/12A61P31/14A61P31/16A61P37/00A61P37/02
Inventor 夏书奇
Owner 夏书奇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap